Liminatus Pharma awaits Nasdaq ruling after saying equity tops $2.5 million threshold

PUBT · 1d ago
Liminatus Pharma awaits Nasdaq ruling after saying equity tops $2.5 million threshold
  • Liminatus Pharma is awaiting a Nasdaq compliance determination on its stockholders’ equity requirement following its merger with InnocsAI.
  • The company believes stockholders’ equity now exceeds $2.5 million, a key threshold for continued Nasdaq listing.
  • Nasdaq will keep monitoring the equity level; a shortfall at the next periodic report could trigger a future delisting risk.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-088380), on July 30, 2026, and is solely responsible for the information contained therein.